Has Michelle Henry, MD received payments from drug or device companies?

Yes. Drug and device makers reported $459,797 in general payments to Michelle Henry, MD across 473 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michelle Henry, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michelle Henry, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michelle Henry, MD

Procedural Dermatology · New York, NYNPI 1154569275

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $301,668 of the $459,797 with a category attached, or 65.6%. AbbVie accounts for 80.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $129,962 and has fallen 88.0% since, to $15,608 in 2025. Among procedural dermatology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$459,797in general payments, 2019–2025

Across 473 payments — averaging $972.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$368K
Galderma Laboratories, L.p.$31K
Merz North America, Inc.$27K
Novartis$12K
Ortho Dermatologics, A Division Of Bausch Health US, LLC$11K
Solta Medical, A Division Of Bausch Health US, LLC$4K
plus $8K from 20 others

$83,424in research payments, 2019–2025

Across 5 payments — averaging $16,685 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$83K

What the payments were for

Consulting fees$301,66866%
Speaking & faculty fees$106,68023%
Travel & lodging$35,3308%
Food & beverage$16,0473%
Education$720%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	194	$368,025
Galderma Laboratories, L.p.	111	$30,949
Merz North America, Inc.	61	$27,429
Novartis	3	$11,555
Ortho Dermatologics, A Division Of Bausch Health US, LLC	9	$10,655
Solta Medical, A Division Of Bausch Health US, LLC	2	$3,506
EPI Health, LLC	2	$2,495
Endo Pharmaceuticals Inc.	5	$1,130
Botanix SB Inc	4	$1,058
Intuitive Surgical	3	$1,043
Sun Pharmaceutical Industries Inc.	22	$504
Revance Therapeutics, Inc.	2	$203
Journey Medical Corporation	10	$191
Pfizer	10	$189
Incyte Corporation	7	$156
Amgen	6	$155
Genentech, Inc.	3	$146
Regeneron Healthcare Solutions, Inc.	3	$75
Johnson & Johnson	3	$70
Arcutis Biotherapeutics, Inc.	4	$68
Sanofi	2	$46
Mayne Pharma Commercial LLC	2	$45
Almirall LLC	2	$41
Organon	1	$27
E.r. Squibb & Sons, L.L.C.	1	$21
Lilly USA, LLC	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BOTOX$204,787
BOTOX COSMETIC$79,379
XEOMIN$12,985
KYBELLA$12,224
ARAZLO$10,500
COSENTYX$8,160
EPSOLAY$6,301
SOOLANTRA$5,465
EPIDUO FORTE$5,115
WYNZORA$2,400
ORACEA$2,148
Da Vinci Surgical System$1,024
SOFDRA$1,000
ASCLERA$288
AKLIEF$172
DAXXIFY$169
Leqselvi$140
Winlevi$140

How this compares

$459,797 in reported general payments places this provider in the 95th percentile of 69 procedural dermatology providers in New York.

See all procedural dermatology providers in New York →

Medicare billing

Part B allowed, 2024

$27,570

Medicare patients

Services billed

325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	44	$1,234
Triamcinolone Acetonide	15	$120
Doxycycline Monohydrate	13	$81

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in New York

Jerry ShapiroNew York$414K
Dendy EngelmanNew York$292K
Evan RiederNew York$210K
Daniel Belkin-HollandNew York$208K
Ariel OstadNew York$36K
Elizabeth HaleNew York$34K
Heidi WaldorfNew York$29K
Robert FinneyNew York$19K
Shera AranoffNew York$8K
Lisa RothmanNew York$7K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →